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Abstract: Not all individuals treated for major depressive disorder (MDD) achieve recovery. 
This observational study examined the recovery rates in MDD patients and the patient character-
istics associated with achieving recovery in a naturalistic clinical setting. Recovery was defined 
as having both clinical and functional remission. Data for this post hoc analysis were taken 
from a 24-week prospective, observational study that involved 1,549 MDD patients. Clinical 
remission was assessed using the 16-item Quick Inventory of Depressive Symptomatology 
Self-Report and functional remission through the Sheehan Disability Scale and no days of 
reduced productivity in the previous week. Generalized estimating equation regression models 
were used to examine the baseline factors associated with recovery during follow-up. Clinical 
and functional remission was achieved in 70.6% and 56.1% of the MDD patients, respectively. 
MDD patients who achieved recovery (52.1%) were significantly less likely to have impaired 
levels of functioning, concurrent medical or psychiatric conditions, low levels of education, or 
nonadherence to therapy at follow-up. The level of functioning during the index episode seems 
to be a better predictor of recovery than symptom severity. Therefore, the level of functioning 
should be considered while determining recovery from depression.
Keywords: remission, functional impairment, clinical remission, course of illness, disability, 
predictors
Introduction
Major depressive disorder (MDD) is a highly prevalent psychiatric condition that 
is associated with significant levels of disability, morbidity, and mortality.1,2 Treat-
ment of MDD traditionally aims to reduce depressive symptoms.3 Consequently, the 
treatment is considered fully effective when complete or near-complete absence of 
the MDD symptoms (for a certain period of time) is achieved.4 However, MDD is 
associated with major and sometimes long-lasting decreased levels of functioning 
and productivity. Approximately 60% of the patients with an MDD report severe or 
very severe functional impairment1 and can continue to experience (partial) impair-
ment long after mood symptoms have been resolved.5 Moreover, patients in remission 
report better functioning than those with mild depression, although their functioning 
is significantly worse than that found in the general population.6 Therefore, remis-
sion of symptoms does not necessarily coincide with completely restored levels of 
functioning. Furthermore, MDD symptoms have differential effects on the level 
of functioning; depressed mood and loss of interest are strongly related to impaired 
functioning while weight problems, mid-nocturnal insomnia, and hypersomnia have 
less impact.7
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There is no commonly agreed definition of remission and 
recovery in MDD. Remission has been defined as a period of 
time in which the patient no longer meets the symptomatic 
criteria for the disorder or has only mild symptoms. Recovery 
is usually defined as sustained remission for a longer period of 
time. The operational criteria encompass 1) severity of symp-
toms assessed through symptom measurement instruments 
(eg, the Hamilton Depression Rating Scale; HAM-D
17
)8,9 
and 2) duration or a certain period of time.10 A reduction in 
symptom severity of $50% during the course of treatment 
became an indicator of clinical response, that is, a clinically 
significant improvement.11 A cutoff score on one of these 
measurements (eg, HAM-D
17
 #7)12 is subsequently used to 
determine remission.13,14 However, specific symptoms con-
sidered and symptom intensity may vary across studies.15
Despite reduction in symptom severity, most patients report 
residual symptoms and continued impaired functioning.15,16 
A survey-based study revealed that the absence of MDD 
symptoms was only one and a less important factor, according 
to patients, in determining remission; more important factors 
were the presence of positive mental health (eg, optimism, 
vigor, self-confidence), a return to one’s usual self, and a 
general sense of well-being.17 In other mental disorders such 
as schizophrenia, quality of life and level of functioning are at 
least as relevant as residual symptoms in defining recovery.18 
In MDD treatment, despite an emerging awareness,15,16,19,20 
functioning and well-being are often neglected in recovery 
measures. In determining recovery, a multidimensional 
outcome of MDD treatment should therefore be considered, 
characterized by symptom severity (clinical remission) as 
well as level of functioning (functional remission).
Previous studies have identified predictors of recovery 
from MDD. However, most of these studies defined recovery 
as “absence of symptoms” or “no more than mild symptoms” 
rather than the achievement of both clinical and functional 
remission over a certain period of time. Increased likelihood 
of recovery, here considered as clinical remission, is associ-
ated with less severe depressive symptoms, lower anxiety 
scores, and lower levels of personality dysfunction,21,22 
whereas factors such as lower economic status, measured 
by education, income, or occupation, concurrent psychiatric 
and medical conditions, longer duration of index episode, 
and older age are associated with a decreased likelihood or 
delayed achievement of clinical remission.23–25
The objectives of this exploratory study were to exam-
ine the recovery rates (defined as having both clinical and 
functional remission) in MDD patients, to describe the char-
acteristics of MDD patients who do achieve recovery and 
those who do not and to examine the baseline characteristics 




This is a post hoc analysis of data from a 6-month, prospec-
tive, observational study aiming to examine treatment-
emergent sexual dysfunction (TESD) and other treatment 
outcomes among patients with MDD who were treated 
with either a selective serotonin reuptake inhibitor (SSRI) 
or a serotonin–norepinephrine reuptake inhibitor (SNRI) in 
actual clinical practice. Between November 15, 2007, and 
November 28, 2008, a total of 1,647 patients at 88 sites were 
enrolled in the study. Of these, 1,549 patients were classified 
as “sexually active patients without sexual dysfunction at 
study entry.” The patients were from the following countries 
and regions: East Asia (China [n=205; 13.2%], Hong Kong 
[n=18; 1.2%], Malaysia [n=33; 2.1%], the Philippines 
[n=113; 7.3%], Taiwan [n=199; 12.8%], Thailand [n=17; 
1.1%], and Singapore [n=2; 0.1%]), the Middle East (Saudi 
Arabia [n=179; 11.6%] and United Arab Emirates [n=135; 
8.7%]), Mexico (n=591; 38.2%), and other regions (Israel 
[n=9; 0.6%] and Austria [n=48; 3.1%]). The study was con-
ducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki26 and, where applicable 
to a study of this nature, are consistent with the International 
Conference on Harmonization Guideline for Good Clinical 
Practice.27 The ethical standards of responsible local commit-
tees and the regulations of the participating countries were 
followed, and wherever required by local law, Ethical Review 
Board (ERB) approval as required for observational studies 
was obtained. The list of ERBs is provided as Supplementary 
material (Table S1). All patients provided informed consent 
for the provision and collection of the data. Further details 
about the study design have been published elsewhere.28,29
Participants
For the purpose of this exploratory study, 1,549 patients (out-
patients) met the inclusion criteria at baseline: 1) presenting 
with an episode of MDD within the normal course of care, 
with MDD diagnosed according to the International Statis-
tical Classification of Diseases 10th revision (ICD-10)30 or 
Diagnostic and Statistical Manual of Mental Disorders 4th 
edition text revision (DSM-IV-TR)31 criteria; 2) at least mod-
erately depressed, defined by Clinical Global Impressions 
of Severity (CGI-S;32 ie, CGI-S score $4); 3) initiating, or 
switching to, any available SSRI or SNRI antidepressant at a 
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treating psychiatrist’s discretion; 4) age $18 years; 5) being 
“sexually active without sexual dysfunction at study entry” 
as defined by the Arizona Sexual Experience Scale (ASEX;33 
ie, the criteria for sexual dysfunction: ASEX total score $19, 
ASEX score $5 on any item, or ASEX score $4 on any 
three items); and 6) not being currently enrolled in another 
ongoing study. Patients were excluded from participation 
if they had 1) a history of treatment-resistant depression; 
2) a past or current diagnosis of major mental disorders (eg, 
schizophrenia-related, bipolar disorder, dementia, or mental 
retardation); or 3) received any antidepressant within 1 week 
(1 month for fluoxetine) prior to study entry, with the excep-
tion of patients receiving an ineffective treatment for whom 
the immediate switch to an SSRI or SNRI antidepressant was 
considered to be the best treatment option.
Data collection and outcome assessment
Data were collected during visits within the normal course 
of care. The routine outpatient visit at which patients were 
enrolled served as the time for baseline data collection. 
Subsequent data collection was targeted at weeks 8, 16, and 
24 following the baseline visit. Patient demographics and 
clinical history were recorded in the baseline assessment. 
Clinical severity of depression was assessed by the treating 
psychiatrists at each visit using the CGI-S and the 16-item 
Quick Inventory of Depressive Symptomatology Self-Report 
(QIDS-SR
16
).34 Higher scores mean greater clinical severity. 
Clinical remission was defined as a QIDS-SR
16
 score #5. 
This is more or less equivalent to a score of #7 on the 
HAM-D
17
.8,9 The Integral Inventory for Depression (IID)35 
was used to measure the emotional and painful symptoms 
of MDD. The IID integrates the emotional items from the 
Mental Health Inventory-5 (MHI-5)36 and the pain-related 
items from the Somatic Symptom Inventory (SSI)37 which 
was modified to add items 27 (joint pain) and 28 (neck pain).20 
Functioning was measured with the Sheehan Disability 
Scale (SDS)38 which evaluates on a scale from 0 to 10 the 
disability experienced by the individual regarding family 
life/home, social life/leisure activities, and work/school. 
The total SDS score was the sum of the three items with 
higher scores meaning greater disability/lower functioning. 
Functional remission was defined as having no or minimum 
disability on the SDS (score ,3 on each of the three sub-
scales) and no days of reduced productivity in the previous 
week. This is a modification of the definition of functional 
remission by Sheehan et al since they based their criteria 
solely on the SDS scores.5 Questionnaires were adminis-
tered by the participating investigators in the local language; 
if unavailable, the questionnaires were translated/adapted to 
different languages. Recovery was defined as having both 
clinical and functional remission. If data are missing for at 
least one of three subscales or days of reduced productivity, 
then functional remission will be missing. Likewise, if data 
on remission or functional remission are missing, recovery 
will be missing. From visit 2 onwards, patients were asked, 
with a single item, about their treatment adherence since last 
assessment. Possible responses were: I never missed taking 
my medication; I missed only a couple of times, but basically 
took all the medicine; I missed the medicine several times, 
but took at least half of it; I took less than half of what was 
prescribed; and I stopped taking the medicine altogether. 
Patients were considered treatment adherent if they reported 
never having missed taking their medication. All the assess-
ment scales have been tested in adult patients with MDD, 
and the psychometric properties have been reported to be 
adequate to excellent.33,34,39–42
statistical analysis
This post hoc study examined baseline predictors of recovery 
defined as clinical and functional remission (ie, measured 
at each post-baseline visit) in the treatment of MDD. Of the 
1,549 patients, 1,297 were included in these post hoc analyses 
because they were not in clinical remission at baseline (ie, 
QIDS-SR
16
 score .5), had at least one post-baseline QIDS-
SR
16
 assessment and initiated treatment with either duloxetine 
or an SSRI as “monotherapy” (this last criterion was included 
for reasons of consistency with previous analyses).
For each measurement, the proportion of patients who 
were in clinical remission, functional remission, or recovery 
was calculated (using the number of patients with no remis-
sion at baseline as denominator). Baseline characteristics as 
well as outcomes of patients who did achieve recovery at some 
point during the study were described and compared using 
chi-square test (categorical variables) and Mann–Whitney 
U test or Kruskal–Wallis test (continuous variables).
Generalized estimating equation (GEE) regression 
models with exchangeable correlation structure were used 
to examine the baseline factors associated with recovery 
during follow-up. The models included recovery as a time-
varying dependent variable, and the following explanatory 
variables were measured at baseline: age (years), gender 
(male/female), QIDS-SR
16
 total score, SDS total score, 
region (East Asia/the Middle East/Mexico/other region), 
and baseline treatment (duloxetine/SSRI). In addition, the 
following baseline variables were included if they appeared 
to be significant at p,0.1 in univariate GEE analyses (ie, one 





explanatory variable at a time): age at first episode of MDD 
(years), marital status (married or living together/never 
married/other), independent living (yes/no), educational 
attainment (# primary school/secondary school or occupa-
tional program/$ university), employment status (full-time/
economically inactive/unemployed or part-time), having had 
MDD episodes in the 24 months prior to baseline (yes/no), 
having any significant psychiatric or medical comorbidity 
(.1/1/none; eg, alcohol abuse, alcohol dependence, cardio-
vascular disease, cancer, chronic pain, chronic movement 
disabilities, endocrine disorder, diabetes mellitus, gastroin-
testinal disorder, neurological disorder, substance abuse, or 
substance dependence), having any painful physical symptom 
at baseline (yes/no), and adherence at visit 2 (yes/no).
Results
Descriptive demographic and clinical 
information
The demographic details and clinical characteristics of 1,297 
patients who entered the study at baseline are presented in 
Table 1. Overall, mean (SD) age of the 1,297 participants 
was 38 (10.6) years, and 56.4% were female. The mean (SD) 
scores were 4.54 (0.68; CGI-S) and 14.65 (4.53; QIDS-SR
16
) 
on clinical severity and 17.78 (6.36; SDS) on disability.
Of the 1,297 participants who entered the study at 
baseline, 1,172 (90.4%) were also assessed at 8 weeks, 
1,128 (87.0%) at 16 weeks, and 1,018 (78.5%) at 24 weeks. 
The course of clinical remission, functional remission, and 
recovery is shown in Figure 1; the proportions of patients 
(using the number of patients at baseline as denominator) 
who achieved clinical remission, functional remission, 
and recovery at 8, 16, and 24 weeks follow-up are shown. 
At week 8, 39.2% of the patients achieved clinical remission, 
while 19.5% of the patients achieved functional remission 
and 15.9% recovery. A comparable pattern was found at 
week 16 of follow-up: 52.9% showed clinical remission but 
the proportion of patients with functional remission (37.7%) 
and recovery (34.2%) lagged behind. At week 24, clinical 
remission was seen in 58.7% of the patients and functional 
remission and recovery in 47.9% and 44.9% of the patients, 
respectively.
During the entire follow-up period (24 weeks), a total 
of 916 patients (70.6%) achieved clinical remission at some 
point during the study and 73.0% of them also achieved 
recovery. Functional remission was achieved at some point 
by 719 patients (56.1%) and 92.9% achieved recovery as 
well. Overall, 668 patients (52.1%) achieved recovery (ie, 
clinical and functional remission) at some point during the 
study period.
Baseline characteristics of patients who 
achieved recovery at some point during 
follow-up
To examine recovery, the baseline characteristics of the 
patients who achieved recovery at some point during follow-up 
(n=668; 52.1%) were compared with those who did not 
achieve recovery at any time point (n=614; 47.9%; Table 2). 
Compared with patients who did not achieve recovery during 
follow-up, patients who did achieve it reported lower levels of 
disability, indicating a higher level of functioning at baseline 
(measured using SDS; p=0.0008). In addition, patients achiev-
ing recovery were more likely to be female (p=0.0295), to be 
married or living together (p=0.0190), to have a higher level 
of education (p=0.0075), to be older at their first MDD episode 
Table 1 Patient characteristics at study entry (baseline)
Baseline characteristic n %




independent living 214 16.50
Marital status
Married, living together 853 65.77
never married 157 12.10
Other 287 22.13
educational attainment
# Primary school 107 8.25
secondary school/occupational program 572 44.10
$ University 618 47.65
employment status
Full-time 718 55.36
economically inactive 338 26.06
Unemployed/part-time 241 18.58
had MDD episode in last 24 months 844 65.07




Painful physical symptoms 680 52.47
Adherence (at visit 2–8 weeks) 803 68.5
iiD total score, mean (sD) 35.54 (7.09)
cgi-s score, mean (sD) 4.54 (0.68)
QiDs-sr16 score, mean (sD) 14.65 (4.53)
sDs score, mean (sD) 17.78 (6.36)
Note: Data are presented as percentage or mean (standard deviation) as 
appropriate.
Abbreviations: sD, standard deviation; MDD, major depressive disorder; cgi-s, 
global impressions of severity; QiDs-sr16, 16-item Quick inventory of Depressive 
symptomatology self-report; sDs, sheehan Disability scale; iiD, integral inventory 
for Depression. 
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(p=0.0023), and to be adherent to therapy (visit at week 8; 
p,0.0001). On the other hand, they were less likely to have 
had an episode of MDD in the last 24 months (p,0.0001) 
or to have concurrent psychiatric and medical conditions 
(p,0.0001) and painful depression-related physical symptoms 
(p=0.0342). No significant differences were found regarding 
the level of clinical severity measured using either the CGI-S 
(p=0.2304) or the QIDS-SR
16
 (p=0.4771).
The results of multiple (GEE) regression, which examined 
the baseline patient characteristics associated with recovery 
and included separate observations for different follow-up 
visits during the 24-week study period, are shown in Table 3. 
The associations described above were largely maintained 
in this logistic regression analysis, except for marital status 
and age at first MDD episode. Patients who at baseline had 
higher levels of disability (odds ratio [OR] =0.95; p,0.001), 
concurrent medical or psychiatric conditions (OR =0.70, 1 
vs no comorbid condition; p=0.011 and OR =0.26, .1 vs 
no comorbid condition; p,0.001), lower levels of educa-
tion (OR =0.52 primary school vs university; p=0.006 
and OR =0.76 secondary school/occupational program vs 
university; p=0.016) and who were nonadherent to therapy 
at week 8 (OR =0.52; p,0.001) were less likely to achieve 
recovery at some point during the follow-up.
Discussion
This study has shown that when patient functioning is taken 
into account, recovery rates for MDD are substantially lower 
than when the definition of recovery is based exclusively on 
the clinical symptoms of depression. The main factors asso-
ciated with the achievement of recovery were adherence to 
treatment, higher levels of education, absence of comorbid 
medical or psychiatric conditions, and lower levels of func-
tional impairment during the index episode.
Regarding the factors associated with recovery, our 
findings are largely consistent with those reported in other 
studies. Nonadherence has previously been recognized as an 
important factor in negative treatment outcomes in MDD.43,44 
Moreover, the treatment adherence rates in our study were 
within the range of those reported elsewhere.45,46 In any case, 
Figure 1 Proportion of patients with (A) clinical remission, (B) functional remission and (C) recovery during follow-up based on total patients at baseline.















independent living, % 0.8735
Yes 16.6 16.3
no 83.4 83.7
Marital status, % 0.0190
Married, living together 69.5 62.4
never married 11.7 12.9
Other 18.9 24.8
educational attainment, % 0.0075
# Primary school 6.3 9.4
secondary school/occupational program 42.1 46.7
$ University 51.6 43.8
employment status, % 0.0664
Full-time 57.2 54.6
economically inactive 26.9 24.6
Unemployed/part-time 15.9 20.8
Age at first episode of MDD, mean (SD), years 34.45 (10.63) 32.97 (11.82) 0.0023
had MDD episode in last 24 months, % 59.7 70.7 ,0.001




Painful physical symptoms, % 49.6 55.5 0.0342
Adherence (at visit 2–8 weeks), % 77.3 57.4 ,0.001
cgi-s, mean (sD) 4.57 (0.70) 4.51 (0.65) 0.2304
QiDs-sr16, mean (sD) 14.43 (4.14) 14.73 (4.81) 0.4771
sDs, mean (sD) 17.20 (6.17) 18.26 (6.46) 0.0008
Note: Data are presented as percentage or mean (standard deviation) as appropriate.
Abbreviations: sD, standard deviation; MDD, major depressive disorder; cgi-s, global impressions of severity; QiDs-sr16, 16-item Quick inventory of Depressive 
symptomatology self-report; sDs, sheehan Disability scale. 
whether recovery is defined as clinical remission or also 
takes into account the patient’s level of functioning, this 
study underlines the fact that nonadherence to treatment has 
a negative impact on the course of depression.
Additionally, the likelihood of achieving recovery was 
negatively associated with lower levels of education. Previ-
ous studies have shown that lower socioeconomic status 
measured either as level of education or as income is associ-
ated with an increased risk of an enduring MDD.23,47
The results show that medical or psychiatric comorbid 
conditions negatively affect the course of depression. Previ-
ous studies have found that 60%–70% of the MDD patients 
have at least one comorbid psychiatric condition and that 
about two thirds report one concurrent medical condition.24 
Though the presence of comorbidities was lower in this 
study, it still indicated a decreased likelihood of recovery 
from depression. This is in line with other studies in which 
comorbid medical conditions as well as psychiatric illnesses 
such as anxiety disorder, dysthymia, personality disorder, and 
substance abuse exerted a negative effect on the course of 
depression.21,22,25,47 Furthermore, a considerable proportion of 
the MDD patients in this study reported painful depression-
related physical symptoms. These have been associated with 
increased severity of MDD and reduced quality of life.20
Remarkably, the level of functioning during the index 
episode was a predictor of achieving recovery while symp-
tomatic severity was not. MDD patients with lower levels 
of functioning at their baseline visit were less likely to 
achieve recovery. This association did not exist for clinical 
severity; the statistical model, adjusted for the influence of 
other factors, showed that baseline clinical severity was 
not a predictor of recovery. Most studies of recovery do 
not consider baseline functioning as a predictor. In a study 
on adolescents with MDD in which recovery was defined 
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as clinical remission lasting for at least 8 weeks, severe 
evaluator-rated depression and higher global functioning 
were identified as predictors.21 In another study, in which 
severity of depression and global functioning (GAF) were 
associated with recovery, they could not be identified as 
predictors of recovery.47 These incongruent outcomes might 
be explained by the presence of residual symptoms during 
clinical recovery.15,16 Moreover, studies with MDD patients 
in clinical remission have shown that the severity of residual 
symptoms was strongly adversely associated with the level 
of functioning.6 Future research should be designed to clarify 
the relationship between residual symptoms and the impaired 
functioning of MDD patients in clinical remission.
The present study defined recovery in terms of achiev-
ing clinical as well as functional remission. Traditionally, 
recovery has been defined as maintenance of clinical remis-
sion over a defined period of time. This definition assumes 
that remission of MDD-related symptoms occurs in paral-
lel with functional improvement. However, this study has 
demonstrated that this is not the case. In accordance with a 
study by Sheehan et al,5 the proportion of MDD patients who 
achieved clinical remission was higher than the proportion 
who achieved functional remission, or recovery operational-
ized as achievement of both clinical and functional remis-
sion. Although it is not clear why our remission rates were 
higher than those published by Sheehan et al,5 one possible 
explanation may be found in the characteristics of our patient 
sample: our observational study was designed primarily to 
examine the frequency of TESD in the treatment of MDD 
and thus included only those patients who were sexually 
active without sexual dysfunction at baseline. It is possible 
that such MDD patients have a better MDD prognosis than 
those with sexual dysfunction.
This study controlled for the effect of medication 
(duloxetine/SSRI) on the course of MDD. However, previous 
findings showed that, compared with SSRI-treated patients, 
duloxetine-treated patients were more likely to achieve clini-
cal remission.48 Likewise, duloxetine-treated patients showed 
significantly more improvement in the level of functioning 
than SSRI-treated patients.49 More research is needed to 
clarify whether duloxetine-treated patients are more likely to 
achieve recovery (ie, clinical and functional remission) than 
their SSRI-treated counterparts, especially as some studies 
report superiority of SNRI (including duloxetine) over SSRI 
treatment,50–52 whereas others report no clinically meaningful 
differences for either medication.31,53,54
The primary outcomes of this study are based on patient-
rated measurements. Patient-rated measurements can provide 
relevant information for treatment evaluation,55 and previous 
research has shown that patient- and clinician-rated measure-
ments are complementary in the assessment of MDD.56,57 
Nevertheless, patients and clinicians may differ in their valu-
ation and assessment of treatment outcomes.58 Accordingly, 
the use of self-report measures can be considered a limitation 
when compared with assessment by a clinician, although it 
is also a strength since it provides a better representation of 
patients’ perspectives.
Our definition of recovery deserves some discussion. 
We defined recovery as a low level of symptoms with no 
impaired functioning. Other conceptualizations, which 
have been mostly applied to severe mental illness, define 
recovery as the development of new meaning and purpose 
in one’s life as one grows beyond the catastrophic effects of 
psychiatric disability.59–61 Nevertheless, in line with other 
studies on recovery of MDD5,6 or severe mental illness,62,63 
the course of clinical remission seems to differ from the 
course of functional remission. Our findings indicate that 
MDD treatment and evaluation should take into account 
not only symptomatic severity but also the level of impaired 
functioning. Clinical and functional remission might be 
associated with different baseline factors and may respond 
to different treatment strategies. Clinical trials should also 
consider functioning in addition to symptomatic severity in 
the assessment of patient outcomes.
Table 3 Baseline factors associated with recovery during follow-up
Variables Adjusted OR  
(95% CI)*
p-value
higher QiDs-sr16 score 1.00 (0.97–1.03) 0.945
higher sDs score 0.95 (0.93–0.97) ,0.001
Being older 1.00 (0.99–1.01) 0.795
Being male (vs female) 1.01 (0.81–1.26) 0.947
Weeks (vs 8)
16 3.88 (3.28–4.58) ,0.001
24 8.59 (7.07–10.45) ,0.001
educational attainment (vs $ university)
secondary school/occupational program 0.76 (0.61–0.95) 0.016
# Primary school 0.52 (0.33–0.83) 0.006
having had MDD episodes in the past  
24 months (vs not)
0.83 (0.66–1.04) 0.107
Having significant comorbidities at baseline
1 0.70 (0.53–0.92) 0.011
.1 0.26 (0.14–0.48) ,0.001
having painful physical symptoms 0.97 (0.78–1.21) 0.776
Being nonadherent to treatment at week 8 0.52 (0.41–0.67) ,0.001
Note: *This logistic regression model with repeated measures included recovery 
as a time-varying variable during follow-up and also adjusted for region and baseline 
treatment.
Abbreviations: Or, odds ratio; MDD, major depressive disorder; QiDs-sr16, 
16-item Quick inventory of Depressive symptomatology self-report; sDs, sheehan 
Disability scale.





The present study has some limitations. First, as men-
tioned above, this study included only those patients who 
were sexually active without sexual dysfunction at baseline 
as the primary objective was to assess the frequency of 
TESD in the treatment of MDD. Sexual dysfunction has been 
reported to be two to three times more prevalent in patients 
with depression compared with the general population,64,65 
and thus our findings may not be immediately generalizable 
to MDD patients as a whole. Further research is warranted 
to examine whether these findings can be replicated in MDD 
patients without such selection criteria. Second, although our 
study prospectively assessed the severity of depression and 
level of functioning in a “real-world” setting, the associa-
tions found in our study may not imply causal relationships 
given its observational design. Third, although this observa-
tional study included more than 1,000 patients from various 
countries, they may not be representative of the patients with 
MDD in each region. Additionally, as the study was not 
designed for that purpose, we did not analyze the cultural 
differences. However, we adjusted for country as a covariate 
in all analyses. Finally, these exploratory analyses were not 
adjusted for a multiplicity of factors; this study should be 
considered hypothesis-generating, not hypothesis-testing.
In conclusion, the present study showed that the level of 
functioning during the index episode of MDD might be a 
better predictor of recovery than symptom severity. There-
fore, it is highly recommended that both symptom severity 
and level of functioning are considered while determining 
recovery in patients with an MDD.
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